This Animal Health API Stock Rises 25% in 1 Year: Merger Done, Promoter Selling Begins
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Viyash Scientific closed at Rs 247.50 on 18 September 2026, up about 25% in a year, with FY26 profit of Rs 224.65 crore against Rs 15.77 crore in FY25.
Quick Answer
Viyash Scientific, formerly SeQuent Scientific, rose approximately 25% in the year to 18 September 2026, closing at Rs 247.50 against Rs 198.59. The gain came from the Rs 8,000 crore merger with Viyash Life Sciences cleared on 18 November 2025, an FY26 operating margin of 20.21%, and a June 2026 quarter net profit of Rs 79.29 crore that was up about 115%. The offset is ownership: promoter entities sold about 11% of the company on 26 August 2026, cutting the Carlyle-controlled stake to 49.78%. This animal health API stock now trades near 40 times trailing earnings with a 7.07% return on equity.
This animal health API stock rose approximately 25% in one year, closing at Rs 247.50 on 18 September 2026 against Rs 198.59 on 18 September 2025. Behind it sit a Rs 8,000 crore merger, a new name, a swing from losses to a Rs 224.65 crore annual profit, and a private equity owner that has just cut its stake below half.
The company is Viyash Scientific Ltd, listed on the NSE as VIYASH and known until January 2026 as SeQuent Scientific. This animal health API stock makes active pharmaceutical ingredients and finished formulations for animal and human health, selling into more than 100 countries from plants in India, Spain, Turkey and Brazil. Viyash Scientific share price closed at Rs 247.50, up about 1.2% on the day, for a market value near Rs 10,784 crore.
Click Here – Get Free Investment Predictions
Animal Health API Stock Returns Across Periods
The one-year price return for this animal health API stock is approximately 25%, computed close to close. No split or bonus occurred in the window. That puts the animal health API stock among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return, dated 18 September 2026.
| Period | Start Close (Rs) | Close on 18 Sep 2026 (Rs) | Price Return |
|---|---|---|---|
| 1 Month (18 Aug 2026) | 254.95 | 247.50 | -3% |
| 6 Months (18 Mar 2026) | 195.32 | 247.50 | +27% |
| 1 Year (18 Sep 2025) | 198.59 | 247.50 | +25% |
| 3 Years (18 Sep 2023) | 90.35 | 247.50 | +174% |
| 5 Years (17 Sep 2021) | 218.80 | 247.50 | +13% |
The three-year figure flatters because the start was distressed, near Rs 90 after two loss-making years. The five-year figure is close to flat, leaving the 2021 peak unrecovered by this animal health API stock.
The 52-week range runs from Rs 178.13 on 23 March 2026 to Rs 298 on 6 July 2026, so the animal health API stock sits roughly 17% below that high and 39% above the low.
Why Did This Animal Health API Stock Rise 25% in One Year?
Because this animal health API stock produced profits the old company never could, inside four quarters. Annual EBITDA went from Rs 338.26 crore in FY25 to Rs 651.88 crore in FY26, and net profit from Rs 15.77 crore to Rs 224.65 crore. Four dated events did most of the work.
NCLT Cleared the Viyash Life Sciences Merger on 18 November 2025
The National Company Law Tribunal approved the amalgamation of Carlyle-backed Viyash Life Sciences with the listed entity on 18 November 2025, a deal valued near Rs 8,000 crore and backed by 99.98% of voting public shareholders. The animal health API stock moved from Rs 214.79 on 7 November to Rs 252 on 19 November 2025.
The Rename Took Effect on 8 January 2026
The SeQuent Scientific name was retired on 8 January 2026 and the NSE symbol changed to VIYASH that month. Cosmetic in itself, it marked the point at which the animal health API stock began reporting as one business, with net debt to trailing EBITDA already down to 0.7 times from 1.4 times.
Q1 FY27 on 11 August 2026 More Than Doubled Net Profit
June 2026 quarter results for the animal health API stock, published on 11 August 2026, showed revenue of Rs 954.67 crore against Rs 798.48 crore, up about 20%, and net profit of Rs 79.29 crore against Rs 36.85 crore, up about 115%. Formulations grew roughly 33% and APIs 4%, with the United States business up about 60% and emerging markets 36%. Net debt fell to approximately Rs 86 crore.
A Rating and an Italian Deal Backed the Animal Health API Stock
A rating agency assigned this animal health API stock AA- with a stable outlook on 22 April 2026, citing an 18.9% operating margin for the first nine months of FY26 against 12.9%. A share purchase agreement for Bio For Life in Italy was signed on 21 July 2026, adding 85 to 90 companion animal products, with closing expected in September 2026.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Financials Behind the Animal Health API Stock
Revenue growth in this animal health API stock has been steady rather than spectacular since the two books were combined. Margin is what changed, from 15.71% in the June 2025 quarter to near 20% a year later as duplicate costs left the manufacturing base.
| Quarter | Revenue (Rs Cr) | EBITDA (Rs Cr) | Operating Margin | Net Profit (Rs Cr) |
|---|---|---|---|---|
| Jun 2025 | 798.48 | 125.61 | 15.71% | 36.85 |
| Sep 2025 | 857.76 | 180.69 | 21.05% | 72.90 |
| Dec 2025 | 872.39 | 189.61 | 17.28% | 48.52 |
| Mar 2026 | 935.88 | 200.17 | 21.76% | 66.38 |
| Jun 2026 | 954.67 | 186.69 | 19.73% | 79.29 |
The annual record of the animal health API stock is starker. FY24 revenue was Rs 1,380.69 crore at a 4.88% margin with a net loss of Rs 29.61 crore, FY25 was Rs 3,039.73 crore at 13.55% with profit of Rs 15.77 crore, and FY26 reached Rs 3,463.86 crore at 20.21% with profit of Rs 224.65 crore.
Cash conversion is the soft spot in this animal health API stock. Operating cash flow was Rs 322.91 crore in FY26 against EBITDA of Rs 651.88 crore, with capital expenditure of Rs 134.72 crore. Debt to equity closed at 0.21 against 0.37, book value is approximately Rs 64 per share, and no dividend has been paid in five years.
What the Animal Health API Stock Actually Sells
Animal health contributed more than half of revenue for this animal health API stock in the first nine months of FY26, split between active ingredients and finished veterinary formulations sold through the Alivira platform. The rest is human health intermediates, APIs and formulations, plus contract work.
The forward argument for the animal health API stock rests on pets rather than livestock. Management points to a pipeline of more than 85 APIs and 81 animal health formulations, and the Italian purchase targets the European pet segment directly. Patent expiries on companion animal molecules running to 2035 are the window this animal health API stock is positioned against, though that revenue arrives in FY28 and beyond.
Shareholding: Carlyle Issued Shares, Then Sold
Ownership of this animal health API stock changed twice in under a year. The merger was settled in fresh equity, lifting the share count from roughly 25 crore to 43.5 crore and pushing the Carlyle-controlled promoter block from about 52% to 61% in the December 2025 quarter. Book value per share fell from Rs 97.15 to Rs 64.52 as a result.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2025 | 52.61% | 6.05% | 12.82% | 28.36% |
| Sep 2025 | 52.33% | 5.90% | 12.91% | 28.69% |
| Dec 2025 | 61.41% | 3.16% | 7.36% | 27.97% |
| Mar 2026 | 61.31% | 2.94% | 7.98% | 27.67% |
| Jun 2026 | 61.31% | 4.50% | 3.76% | 30.34% |
On 26 August 2026 the promoter vehicles of this animal health API stock, CA Harbor Investments and CA Hull Investments, sold 5,03,65,847 shares in the open market, about 11.03% of capital, with roughly Rs 1,258 crore changing hands. Combined promoter holding fell to 49.78% of voting capital, and Viyash Scientific share price dropped from Rs 278.35 on 25 August to Rs 263.40 on 26 August.
Domestic institutional holding thinned from 12.82% in March 2025 to 3.76% in June 2026, while foreign holding rose from 2.94% to 4.50%.
Risks in This Animal Health API Stock
Several of these are live now and deserve weighing against a 25% gain in Viyash Scientific share price.
Promoter overhang. Carlyle still holds close to half the company through two vehicles. A further sell-down is possible, and the August 2026 sale took the price down about 5% in a session, with this animal health API stock still below the pre-sale level three weeks later.
Regulatory exposure. The group sells into the United States and Europe, so its plants are open to US FDA and EU GMP inspection. An April 2026 credit rating note warned that observations by agencies such as the US FDA could hurt operations. No fresh adverse US FDA action was found in the twelve months reviewed, and the Visakhapatnam animal health active ingredient plant has held US FDA clearance since 2017, but the risk is structural.
A thin return on equity. The trailing price to earnings multiple is approximately 40 against an industry figure near 37, while return on equity is 7.07%. FY26 earnings per share was Rs 4.01 after losses of Rs 1.44 in FY24 and Rs 4.88 in FY23, so one good year does not settle the case for this animal health API stock.
Working capital and integration. Receivables absorbed roughly Rs 284 crore of cash in FY26 and working capital Rs 329 crore in total. Merger synergies were guided at Rs 125 crore to Rs 150 crore over 12 to 18 months but were annualising nearer Rs 50 crore to Rs 60 crore, so part of the assumed saving is not yet banked.
Liquidity and volatility. At about Rs 10,784 crore of market value this animal health API stock is a small cap whose 52-week range spans Rs 178.13 to Rs 298. Turnover is lumpy, with sessions in May and August 2026 at many multiples of normal volume, so exits in size move the price. Currency risk from Turkey and Brazil adds swing.
Download the Univest iOS App or Univest Android App to track the Viyash Scientific share price live
Viyash Scientific Share: Analyst View
Coverage of this animal health API stock is limited, which is normal after a change of name, share count and controlling stake inside nine months. What exists has turned more positive since the FY26 results, mainly on margin and near-zero net debt.
Viyash Scientific Share Price Target
A domestic brokerage carried a buy rating during 2026 with a Viyash Scientific share price target of Rs 330, implying approximately 33% upside from Rs 247.50. That is the only verified published target found, so treat it as one view and not a consensus. A Viyash Scientific share price target set before the August 2026 promoter sale may not reflect the supply since added.
Working from levels instead, resistance for the animal health API stock is the 52-week high of Rs 298 and support the Rs 245 to Rs 250 band held through September 2026. A break below Rs 236.85, the low of 16 September 2026, would reopen the March low.
Valuation of the Animal Health API Stock
At roughly 40 times trailing earnings the market is paying this animal health API stock for FY27 and FY28, not for the record. Trailing earnings per share is Rs 6.06. Hold the June quarter profit of Rs 79.29 crore flat for a year and the annualised figure is near Rs 317 crore, closer to 34 times.
That is the bull case for this animal health API stock: margins hold, the Italian pet portfolio adds revenue from FY28, and the multiple compresses on rising profit rather than a falling share price. The bear case is that a 20% operating margin has been achieved in only one of the last five years, and the promoter is a financial owner intent on reducing.
Other Stocks to Track From the Same Return Screen
Beyond this animal health API stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as IOL Chemicals with a 1-year return of 65.96%, Inox India at 65.66% and Indiabulls at 65.20%.
Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this animal health API stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.
Conclusion
A 25% year in this animal health API stock understates how much has changed and overstates how settled things are. The merger is complete, the name is changed, the balance sheet is close to debt free, and profit has moved from a Rs 29.61 crore loss two years ago to Rs 224.65 crore in FY26. That explains the re-rating in this animal health API stock.
Ownership is the open question and the largest single variable in Viyash Scientific share price over the next year. Watch three things in this animal health API stock: quarterly operating margin, the closing of the Italian pet portfolio, and any further promoter block sale. Consult a registered investment adviser before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the 1-year return of this animal health API stock?
Ans. This animal health API stock returned approximately 25% for the year to 18 September 2026, from Rs 198.59 to Rs 247.50, with no split or bonus in the window. The three-year return is about 174%, the five-year about 13%.
Why was SeQuent Scientific renamed Viyash Scientific?
Ans. The name changed on 8 January 2026 after Carlyle-backed Viyash Life Sciences merged into the listed company, and the NSE symbol moved from SEQUENT to VIYASH that month. The scheme was cleared on 18 November 2025.
How much does Carlyle own in Viyash Scientific now?
Ans. Combined promoter holding was 49.78% of voting capital after the 26 August 2026 open market sale, down from 61.31%. The vehicles CA Harbor Investments and CA Hull Investments sold 5,03,65,847 shares, about 11.03% of capital.
Is there a verified Viyash Scientific share price target?
Ans. One domestic brokerage published a buy rating with a target of Rs 330 during 2026, about 33% above the close of Rs 247.50. It is a single view rather than a consensus, and the 52-week high of Rs 298 from 6 July 2026 is the nearer reference.
What does this animal health API stock actually make?
Ans. It makes active pharmaceutical ingredients and finished formulations for animal and human health. Animal health was more than half of revenue in the first nine months of FY26.
Has Viyash Scientific received any US FDA observations recently?
Ans. No fresh adverse US FDA action was found for the twelve months to 18 September 2026, and the Visakhapatnam animal health active ingredient facility has held US FDA clearance since 2017. An April 2026 credit rating note still flagged US FDA and EU GMP scrutiny as a standing risk.
What were the FY26 financials of Viyash Scientific?
Ans. FY26 revenue was Rs 3,463.86 crore with EBITDA of Rs 651.88 crore and net profit of Rs 224.65 crore. Operating margin was 20.21% against 13.55% in FY25, debt to equity closed at 0.21, and no dividend was paid.
What are the main risks in this animal health API stock?
Ans. The largest is promoter supply, since a financial owner still holds close to half the equity after selling 11% in August 2026. Others are US FDA and EU GMP exposure, a multiple near 40 against a 7.07% return on equity, slow cash conversion, and small-cap liquidity risk.
